Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q16613
UPID:
SNAT_HUMAN
Alternative names:
Aralkylamine N-acetyltransferase
Alternative UPACC:
Q16613; A0AVF2; J3KMZ5; Q562F4
Background:
Serotonin N-acetyltransferase, also known as Aralkylamine N-acetyltransferase, plays a pivotal role in the regulation of the night/day rhythm of melatonin production in the pineal gland. It catalyzes the N-acetylation of serotonin into N-acetylserotonin, a crucial step in melatonin synthesis.
Therapeutic significance:
Understanding the role of Serotonin N-acetyltransferase could open doors to potential therapeutic strategies. Its critical function in melatonin synthesis suggests its potential impact on sleep disorders and circadian rhythm disruptions.